ID   BCPAP-R
AC   CVCL_A8S1
DR   cancercelllines; CVCL_A8S1
DR   Wikidata; Q102113611
RX   PubMed=32666385;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Tyr (c.775G>T); ClinVar=VCV000634680; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
DI   NCIt; C6040; Poorly differentiated thyroid gland carcinoma
DI   ORDO; Orphanet_100088; Thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0153 ! B-CPAP
SX   Female
AG   76Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 8
//
RX   PubMed=32666385; DOI=10.1007/s12020-020-02417-y;
RA   Run L., Wang L.-P., Nong X.-T., Li N., Huang X., Xiao Y.;
RT   "Involvement of HMGB1 in vemurafenib resistance in thyroid cancer
RT   cells harboring BRAF (V600E) mutation by regulating excessive
RT   autophagy.";
RL   Endocrine 71:418-426(2021).
//